Company: ECIA
Filing Date: 2025-07-10
Form Type: 10-K
Source: 0001079973-25-001132
Chunk: 24

Company: ENCISION INC
Filing Date: 2025-07-10
Form: 10-K
Item: Item 1
Chunk 24
---
 not repurchase any of our equity securities
during the period covered by this Annual Report.

Item 6. [Reserved]

14 

Item
7. Management's Discussion and Analysis of Financial Condition and Results of Operations

Certain statements
contained in this section are not historical facts, including statements about our strategies and expectations about new and existing
products, market demand, acceptance of new and existing products, technologies and opportunities, market and industry segment growth,
and return on investments in products and markets. These statements are forward looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995 and involve substantial risks and uncertainties that may cause actual results to differ materially from
those indicated by the forward looking statements. All forward looking statements in this section are based on information available to
us on the date of this document, and we assume no obligation to update such forward looking statements. Readers of this Form 10-K are
strongly encouraged to review the section entitled “Risk Factors”.

Outlook

Installed Base of AEM Monitoring Equipment.
We believe that we are gaining more awareness in medico-legal circles and publications and from presentations at medical meetings. We
believe that improvement in the quality of sales representatives carrying our AEM products line, along with increased marketing efforts
and the introduction of new products, may provide the basis for increased sales and continuing profitable operations. However, these measures,
or any others that we may adopt, may not result in either increased sales or continuing profitable operations.

Possibility of Operating Losses. We have
an accumulated deficit of $22,765,245 at March 31, 2025. We have made significant strides toward improving our operating results. However,
due to the ongoing need to develop new products, the need to develop, optimize and train our sales distribution network and the need to
increase sustained sales to a level adequate to cover fixed and variable operating costs, we may operate at a net loss in future periods.

Sales Growth. We expect to generate increased
sales in the U.S. from sales to new hospital customers and to grow AEM instrumentation sales to existing accounts. In fiscal year 2026,
we will focus on growing our AEM franchise through a campaign focused on the clinical, economic and safety benefits of AEM technology,
a medico-legal initiative and our new AEM products. In addition, prior years’ efforts in vertical integration have given us three
core competencies – electrosurgery, instrument design, and manufacturing – which we expect will allow us